Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.10 per share
-
Shares outstanding
-
1,147,663,152
-
Number of holders
-
434
-
Total 13F shares, excl. options
-
640,277,265
-
Shares change
-
-20,324,716
-
Total reported value, excl. options
-
$5,906,782,225
-
Value change
-
-$439,059,091
-
Put/Call ratio
-
192%
-
Number of buys
-
196
-
Number of sells
-
-234
-
Price
-
$9.23
Significant Holders of TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA) as of Q2 2019
592 filings reported holding TEVA - TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share as of Q2 2019.
TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA) has 434 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 640,277,265 shares
of 1,147,663,152 outstanding shares and own 56% of the company stock.
Largest 10 shareholders include Capital Research Global Investors (130,892,229 shares), WELLINGTON MANAGEMENT GROUP LLP (62,933,826 shares), FRANKLIN RESOURCES INC (61,643,131 shares), Berkshire Hathaway Inc (43,249,295 shares), Capital World Investors (39,605,476 shares), BlackRock Inc. (34,958,397 shares), ABRAMS CAPITAL MANAGEMENT, L.P. (18,046,356 shares), STATE STREET CORP (12,583,179 shares), RENAISSANCE TECHNOLOGIES LLC (9,786,063 shares), and PRICE T ROWE ASSOCIATES INC /MD/ (9,553,328 shares).
This table shows the top 434 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.